ClinicalTrials.gg
CompletedNCT06248008Updated Dec 1, 2025

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

A Phase 3 interventional study of ASC40 in Acne, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Enrollment
9th of 33
240 · median 100
Started
2024
with 4 others
Phase 3
8 of 35
1 open now
Registered
21st of 35
by date
Lead sponsor
3 of 35
Ascletis Pharmaceuticals Co., Ltd.

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2024, is one of 8 in phase 3, and was the 21st registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

03

Conditions studied

  • Acne

Browse trials for

Keywords

  • Acne
  • ASC40
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have successfully completed a 12-week Phase III study of ASC40-303;
  • Have fully understood this research and voluntarily signed the ;
  • The fertile male and female subjects of reproductive age agreed to use effective from the time they signed the informed consent until 3 months after the final administration of the investigationa drug;
  • Subjects are willing and able to complete the study, understand and comply with the study requirements, comply with the study requirements restrictions and related education, use the drug as prescribed by the physician, and follow up according to the study schedule.

Exclusion criteria

Exclusion Criteria:

  • Discontinue participation in the ASC40-303 Phase III study for any reason;
  • Are receiving/planning to receive any systemic acne medications, systemic retinoids, systemic , or any androgen/antiandrogen therapy (e.g., testosterone, spironolactone);
  • Pregnant, nursing, or planning a pregnancy during the study period;
  • Have major complications (including abnormalities in clinical laboratory tests), mental disorders, or other factors deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    ASC40 50mg

    ASC40 50mg, up to 40 weeks of treatment.

    Drug: ASC40

Interventions

  • DrugASC40

    ASC40 tablets orally once daily

06

What researchers measure

Primary outcomes

  1. Number and percentage of subjects with treatment emergent adverse events (TEAE)

    The number and percentage of all subjects with treatment emergent adverse events (TEAE) from the first dose to 40 weeks of treatment.

    Time frame: From the first dose to 40 weeks of treatment.

  2. Number and percentage of subjects with serious adverse event (SAE).

    Number and percentage of subjects with serious adverse event (SAE) from the first dose to 40 weeks of treatment.

    Time frame: From the first dose to 40 weeks of treatment.

  3. Number and percentage of subjects who discontinued due to adverse events.

    Number and percentage of subjects who discontinued due to adverse events from the first dose to 40 weeks of treatment.

    Time frame: From the first dose to 40 weeks of treatment.

Secondary outcomes

  1. At the end of the visit, the number of people whose IGA rating had decreased by at least 2 points from the baseline period of the study.

    At the end of the visit, the number of subjects whose IGA rating had decreased by at least 2 points from the baseline period of the study.

    Time frame: up to 40 weeks.

  2. At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1.

    At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1 among all subjects.

    Time frame: up to 40 weeks.

  3. Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.

    Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.

    Time frame: up to 40 weeks.

  4. Percentage change in total inflammatory skin lesion count at the end of the visit compared to the baseline period of the study.

    Percentage change in total inflammatory skin lesion count for all subjects at the end of the visit compared to the baseline period of the study.

    Time frame: up to 40 weeks.

07

Study locations

1 site
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2025, 18 months.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 18 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 8, 2024
StartActual
Apr 18, 2024
Primary completionActual
Nov 12, 2025
CompletionActual
Nov 12, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06248008
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Apr 18, 2024
Primary completion
Nov 12, 2025
Completion
Nov 12, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion